| 1. |
ADVANCE NEXT: Phase 3 study of intravenous efgartigimod in primary immune thrombocytopenia （口頭発表，一般） 2025/06/23
|
| 2. |
Effect of Intravenous Efgartigimod on Immature Platelet Fraction inPrimary Immune Thrombocytopenia （口頭発表，一般） 2025/06/23
|
| 3. |
LUNA3 open-label period: First efficacy/safety with rilzabrutinib in previously treated ITP adults （口頭発表，一般） 2025/06/23
|
| 4. |
Platelet responses per IWG criteria for LUNA3 rilzabrutinib vs placebo in primary ITP patients （口頭発表，一般） 2025/06/22
|
| 5. |
Early initiation of TPO-RA reduces total corticosteroid dose in adult ITP: Japanese database analysis （ポスター，一般） 2025/06/21
|
| 6. |
Health-Related Quality of Life and Joint Health with Giroctocogene Fitelparvovec Gene Therapy （口頭発表，一般） 2025/06/20
|
| 7. |
エクリズマブから切替えたaHUS患者のラブリズマブ製造販売後調査の解析 （ポスター，一般） 2025/06/20
|
| 8. |
PHASE 3 LUNA3 STUDY: FIRST EFFICACY/SAFETY REPORT OF LONG-TERM EXTENSION PERIOD WITH RILZABRUTINIB IN ADULTS WITH PERSISTENT/CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) （口頭発表，一般） 2025/06/13
|
| 9. |
Effect of Efgartigimod IV on Immature Platelet Count Fraction in Primary Immune Thrombocytopenia （口頭発表，一般） 2025/06/12
|
| 10. |
Efgartigimod IV for the Treatment of Primary Immune Thrombocytopenia: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study With Open-Label Period (ADVANCE NEXT) （口頭発表，一般） 2025/06/12
|
| 11. |
CLINICAL FACTORS ASSOCIATED WITH RESPONSE TO RILZABRUTINIB, A BRUTON TYROSINE KINASE (BTK) INHIBITOR, IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP) TREATED IN THE PHASE 3 LUNA3 STUDY （口頭発表，一般） 2025/06/11
|
| 12. |
Ravulizumab in atypical haemolytic uraemic syndrome: analysis of quality of life outcomes in adult and pediatric phase 3 trials （ポスター，一般） 2025/06/04
|
| 13. |
Efficacy and safety of ora bruton tyrosine kinase inhibitor (BTKi) rilzabrutinib in adults with previously treated immune thrombocytopenia (ITP): a phase 3, placebo controlled, parallel group, multi-center study (LUNA3) （口頭発表，一般） 2025/03/29
|
| 14. |
Bleed protection after giroctocogene fitelparvovec infusion in adults with moderately severe to severe hemophilia A in the phase 3 AFFINE trial. （ポスター，一般） 2025/02/04
|
| 15. |
Clinical management of factor VIII elevations above normal ranges post giroctocogene fitelparvovec in Phase 3 AFFINE study （口頭発表，一般） 2025/02/04
|
| 16. |
Efficacy and safety of oral bruton tyrosine kinase inhibitor (BTKi) rilzabrutinib in adults with previously treated immune thrombocytopenia (ITP): a phase 3, placebo-controlled, parallel-group, multicenter study (LUNA3) （口頭発表，一般） 2024/12/08
|
| 17. |
Improved health-related quality of life (HR-QOL) with oral bruton tyrosine kinase inhibitor (BTKi) rilzabrutinib vs placebo in adults with previoulsy treated immune thrombocytopenia (ITP): phase 3 LUNA3 multicenter study （ポスター，一般） 2024/12/08
|
| 18. |
Intravenous efgartigimod for the treatment of primary immune thrombocytopenia in adults: a planned, phase 3, randomised, double-blindded, placebo-controlled, parallel-arm study with open label period (ADVANCE NEXT) （口頭発表，一般） 2024/12/08
|
| 19. |
Safety and efficacy of efgartigmod in primary immune thrombocytopenia: ADVANCE IV+ 2 year analysis （口頭発表，一般） 2024/11/06
|
| 20. |
Ravulizumab in atypical hemolytic uremic syndrome: final analysis of efficacy and safety outcomes in two phase 3 trials. （口頭発表，一般） 2024/10/23
|
| 21. |
Baseline characteristics of Asian patients with persistent and chronic ITP enrolled in LUNA 3 trial （口頭発表，一般） 2024/10/12
|
| 22. |
Safety and efficacy of efgartigimod in primary immune thrombocytopenia: ADVANCE+ interim 2 year analysis （口頭発表，一般） 2024/10/12
|
| 23. |
BASIC CHARACTERISTICS OF ADULT PATIENTS WITH PREVIOUSLY TREATED IMMUNE THROMBOCYTOPENIA ENROLLED IN LUNA 3 PHASE 3 PLACEBO-CONTROLLED STUDY OF RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR （ポスター，一般） 2024/10/11
|
| 24. |
Post hoc analysis of ADAMTS13 activity and inhibitors in a phase 2/3 sutdy in Japanese patients with iTTP treated with caplacizumab （ポスター，一般） 2024/06/22
|
| 25. |
Time to platelet count response afetr IV efgartigimod in primary ITP （口頭発表，一般） 2024/06/15
|
| 26. |
Basic characteristics of adult patients with previously treated immune thrombocytopenia enrolled in LUNA3 phase 3 placebo-controlled study of rilzabrutinib, an oral bruton tyrosine kinase inhibitor （抄録提出，一般） 2024/06/13
|
| 27. |
Inhibition of complement C1s with sutimlimab in patients with cold agglutinin disease (CAD): 2 year follow up from the CARDINAL study （口頭発表，一般） 2023/06/09
|
| 28. |
Long term safety and efficacy of efgartigimod in patients with primary immune thrombocytopenia: interim results of the ADVANCE+ study （口頭発表，一般） 2023/06/08
|
| 29. |
Intravenous efgartigimod in adults with primary immune thrombocytopenia: results from the ADVANCE IV trial. （口頭発表，一般） 2023/04/25
|
| 30. |
SARS-Cov-2ワクチン接種後に発症した後天性血栓性血小板減少性紫斑病 （口頭発表，一般） 2023/03/11
|
| 31. |
後天性血友病A患者の出血リスクが高い経皮腎瘻造設術に対するエミシズマブとrFVIIaによる周術期管理 （口頭発表，一般） 2023/03/11
|
| 32. |
Efficacy and safety of intravenous Efgartigimod in adults with primary immune thrombocytopenia: results of ADVANCE IV, a Phase 3, multicentr, double-blinded, placebo-controlled, randomized clinical trial （口頭発表，一般） 2022/12/11
|
| 33. |
HELLP症候群との鑑別を要する妊娠関連TMA （口頭発表） 2022/10/29
|
| 34. |
Two-Year Efficacy and Safety of Ravulizumab in Adults and Children with Atypical Hemolytic Uremic Syndrome: Analysis of Two Phase 3 Studies （ポスター，一般） 2022/10/17
|
| 35. |
後天性血栓性血小板減少性紫斑病（TTP）診断と新規治療：抗VWF抗体カプラシズマブ （口頭発表） 2022/10/16
|
| 36. |
Efficacy and safety of caplacizumab for thrombotic thrombocytopenic purpura: Japanese Phase 2/3 study （口頭発表，一般） 2022/10/15
|
| 37. |
Phamacokinetic and pharmacodynamic simulations guide selection of the dose for administration of efgartigimod PH20 subcutaneously in a Phase 3 clinical trial in patients with primary immune thrombocytopenia （口頭発表，一般） 2022/09/26
|
| 38. |
Inhibition of complement C1s with sutimlimab in patients with cold agglutinin disease (CAD): a 2 year follow up from the CARDINAL study （口頭発表，一般） 2022/06/10
|
| 39. |
Inhibition of complement C1s with sutimlimab in patients with cold agglutinin diseasse (CAD): 2 year follow up from the CADRINAL study （口頭発表，一般） 2022/06/10
|
| 40. |
Inhibition of complement C1s with sutimlimab in patients with cold agglutinin disease, 2 year follow up from the CARDINAL study （ポスター，一般） 2022/06/09
|
| 41. |
Inhibition of complement C1s with sutimlimab in patients with cold aggulutinin disease , results following 9 week wash out period in phase 3 cardinal study. （ポスター，一般） 2022/06/09
|
| 42. |
Sutimlimab, a complement C1s inhibitor, provides sustained improvements in patient-reported outcomes in patients with cold agglutinin disease, 2 year follow up from the CARDINAL study （ポスター，一般） 2022/06/09
|
| 43. |
Eculizumab for adult patients with atypical haemolytic uremic syndrome: full dataset analysis of post-marketing surveillance in Japan （口頭発表，一般） 2022/05/20
|
| 44. |
La modélisation pharmacocinétique-pharmacodynamique supporte la sélection de la dose d'efgartigimod à administrer par voie sous-cutanée dans un essai clinique de phase 3 chez des patients atteints de purpura thrombopénique immunologique （ポスター，一般） 2021/12/16
|
| 45. |
Two year efficacy and safety of ravulizumab in adults and children with atypical HUS: analysis of two phase 3 studies. （口頭発表，一般） 2021/12/06
|
| 46. |
Phamakokinetic and pharmakodynamic simulations guide selection of the dose for administration of Efgartigimod PH20 subctutaneously in a phase 3 clinical trial in patients with primary immune thrombocytopenia （口頭発表，一般） 2021/12/05
|
|
5件表示
|
|
全件表示(46件)
|
